Patients with prostate cancer in England will now have early access to a drug that can delay the need for chemotherapy.
The National Institute for Health and Care Excellence (NICE) has approved the drug abiraterone for men with advanced prostate cancer, who have not yet had chemotherapy.
The drug – developed by UK scientists – can delay the disease’s progression, help to prolong life, and provide a better quality of like with less fatigue and pain. It has been available across the UK for men after chemotherapy since 2012.
Read the full article at Cancer Research UK